US Dry Age-Related Macular Degeneration AMD Market

ID: MRFR/LS/12338-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
US Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Users (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) -Forecast to 2035
US Dry Age-Related Macular Degeneration AMD Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.3%
2024 Market Size$ 1,332.8 Million
2025 Market Size$ 1,443.42 Million
2035 Market Size$ 3,203.89 Million
Key Players
Regeneron Pharmaceuticals
Novartis
Roche
Bayer
Pfizer
Alcon
Trends
  • Emergence of Novel Therapies
  • Increased Patient Awareness
  • Technological Advancements in Diagnostics
Opportunities
  • Aging Population Dynamics
  • Rising Healthcare Expenditure
  • Increased Focus on Preventive Care
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Security, Access Control and Robotics, BY Stages (USD Million) | |
      1. 4.1.1 Early Age-Related Macular Degeneration | |
      2. 4.1.2 Intermediate Age-Related Macular Degeneration | |
      3. 4.1.3 Late Age-Related Macular Degeneration |
    2. 4.2 Security, Access Control and Robotics, BY Age Group (USD Million) | |
      1. 4.2.1 Above 75 Years | |
      2. 4.2.2 Above 60 Years | |
      3. 4.2.3 Above 40 Years |
    3. 4.3 Security, Access Control and Robotics, BY Route of Administration (USD Million) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Injectables |
    4. 4.4 Security, Access Control and Robotics, BY End Users (USD Million) | |
      1. 4.4.1 Hospitals & Clinics | |
      2. 4.4.2 Diagnostic Centers | |
      3. 4.4.3 Academic & Research Institutes 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Regeneron Pharmaceuticals (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Novartis (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Roche (CH) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Bayer (DE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Pfizer (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Alcon (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Horizon Therapeutics (IE) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Apellis Pharmaceuticals (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY STAGES |
    6. 6.3 US MARKET ANALYSIS BY AGE GROUP |
    7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 US MARKET ANALYSIS BY END USERS |
    9. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS |
    12. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS |
    14. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS |
    15. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY STAGES, 2024 (% SHARE) |
    16. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY STAGES, 2024 TO 2035 (USD Million) |
    17. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY AGE GROUP, 2024 (% SHARE) |
    18. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY AGE GROUP, 2024 TO 2035 (USD Million) |
    19. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    20. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
    21. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USERS, 2024 (% SHARE) |
    22. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USERS, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY STAGES, 2025-2035 (USD Million) | |
      2. 7.2.2 BY AGE GROUP, 2025-2035 (USD Million) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
      4. 7.2.4 BY END USERS, 2025-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

US Dry Age-Related Macular Degeneration AMD Market Segmentation

US Dry Age-Related Macular Degeneration AMD Market By Stages (USD Million, 2025-2035)

  • Early Age-Related Macular Degeneration
  • Intermediate Age-Related Macular Degeneration
  • Late Age-Related Macular Degeneration

US Dry Age-Related Macular Degeneration AMD Market By Age Group (USD Million, 2025-2035)

  • Above 75 Years
  • Above 60 Years
  • Above 40 Years

US Dry Age-Related Macular Degeneration AMD Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Injectables

US Dry Age-Related Macular Degeneration AMD Market By End Users (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.